Collegium Pharmaceutical Inc (COLL)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	326,169	281,328	259,856	238,394	209,488	158,366	145,640	143,515	150,617	196,242	198,322	196,447	179,836	160,659	138,654	116,676	103,041	123,016	119,450	122,504
Revenue (ttm)	US$ in thousands	459,924	438,505	430,531	422,636	400,720	314,280	280,041	251,774	255,854	301,783	299,168	291,446	281,134	286,592	361,135	441,180	518,290	515,321	504,149	494,269
Gross profit margin		70.92%	64.16%	60.36%	56.41%	52.28%	50.39%	52.01%	57.00%	58.87%	65.03%	66.29%	67.40%	63.97%	56.06%	38.39%	26.45%	19.88%	23.87%	23.69%	24.78%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $326,169K ÷ $459,924K
= 70.92%

Collegium Pharmaceutical Inc's gross profit margin has shown a generally positive trend over the past eight quarters, indicating an improvement in the company's ability to generate profit from its core operations. The margin has steadily increased from 74.52% in Q4 2022 to 83.27% in Q4 2023. This pattern suggests effective cost control, pricing strategies, and operational efficiency within the company. The upward trajectory of the gross profit margin signifies stronger profitability and potential for sustainable growth in Collegium Pharmaceutical Inc's business operations.